Kris Cameron Wood

Wood

Associate Professor of Pharmacology and Cancer Biology

Appointments and Affiliations

  • Associate Professor of Pharmacology and Cancer Biology
  • Member of the Duke Cancer Institute

Contact Information

  • Email Address: kris.wood@duke.edu
  • Websites:

Education

  • Ph.D. Massachusetts Institute of Technology, 2007
  • B.S. University of Kentucky, Lexington, 2002

Courses Taught

  • BIOLOGY 728A: University Program in Genetics and Genomics Biological Solutions Module I
  • CMB 710E: Cell & Molecular Biology Module V
  • CMB 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • MGM 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis
  • PHARM 393: Research Independent Study
  • PHARM 394: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 495: Research Independent Study
  • PHARM 818: Molecular Mechanisms of Oncogenesis
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I

In the News

Representative Publications

  • Joh, DY; Heggestad, JT; Zhang, S; Anderson, GR; Bhattacharyya, J; Wardell, SE; Wall, SA; Cheng, AB; Albarghouthi, F; Liu, J; Oshima, S; Hucknall, AM; Hyslop, T; Hall, AHS; Wood, KC; Shelley Hwang, E; Strickland, KC; Wei, Q; Chilkoti, A, Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates., Npj Breast Cancer, vol 7 no. 1 (2021) [10.1038/s41523-021-00290-0] [abs].
  • Su, A; Ling, F; Vaganay, C; Sodaro, G; Benaksas, C; Dal Bello, R; Forget, A; Pardieu, B; Lin, KH; Rutter, JC; Bassil, CF; Fortin, G; Pasanisi, J; Antony-Debré, I; Alexe, G; Benoist, J-F; Pruvost, A; Pikman, Y; Qi, J; Schlageter, M-H; Micol, J-B; Roti, G; Cluzeau, T; Dombret, H; Preudhomme, C; Fenouille, N; Benajiba, L; Golan, HM; Stegmaier, K; Lobry, C; Wood, KC; Itzykson, R; Puissant, A, The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies., Cancer Discov, vol 10 no. 12 (2020), pp. 1894-1911 [10.1158/2159-8290.CD-19-0970] [abs].
  • Vaseva, AV; Bandyopadhyay, A; Del Pozo, V; Goodwin, CM; Gautam, P; Wennerberg, K; Wood, KC; Chen, Y; Der, CJ; Houghton, PJ, Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma, Cancer Research, vol 80 no. 14 (2020), pp. 72-72 [abs].
  • Ozkan-Dagliyan, I; Diehl, JN; George, SD; Schaefer, A; Papke, B; Klotz-Noack, K; Waters, AM; Goodwin, CM; Gautam, P; Pierobon, M; Peng, S; Gilbert, TSK; Lin, KH; Dagliyan, O; Wennerberg, K; Petricoin, EF; Tran, NL; Bhagwat, SV; Tiu, RV; Peng, S-B; Herring, LE; Graves, LM; Sers, C; Wood, KC; Cox, AD; Der, CJ, Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers., Cell Reports, vol 31 no. 11 (2020) [10.1016/j.celrep.2020.107764] [abs].
  • Vaseva, AV; Bandyopadhyay, A; Del Pozzo, V; Goodwin, CM; Gautam, P; Wennerberg, K; Wood, KC; Der, CJ; Houghton, PJ, Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma., Molecular Cancer Research : Mcr, vol 18 no. 5 (2020), pp. 59-60 [abs].